These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2090682)

  • 1. Study on hepatotoxicity and other side-effects of antituberculosis drugs.
    Taneja DP; Kaur D
    J Indian Med Assoc; 1990 Oct; 88(10):278-80. PubMed ID: 2090682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity to different antituberculosis drug combinations.
    Aziz S; Agha F; Hassan R; Fairoz SA; Hassan K
    J Pak Med Assoc; 1990 Dec; 40(12):290-4. PubMed ID: 2126569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver injury during antituberculosis treatment: an 11-year study.
    Døssing M; Wilcke JT; Askgaard DS; Nybo B
    Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of anti-tuberculosis drug-induced hepatotoxicity.
    Tahaoğlu K; Ataç G; Sevim T; Tärün T; Yazicioğlu O; Horzum G; Gemci I; Ongel A; Kapakli N; Aksoy E
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):65-9. PubMed ID: 11263519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis in patients with surgical complications of pulmonary tuberculosis.
    Ansari MM; Beg MH; Haleem S
    Indian J Chest Dis Allied Sci; 1991; 33(3):133-8. PubMed ID: 1794880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for hepatotoxicity induced by antituberculosis drugs.
    Devoto FM; González C; Iannantuono R; Serra HA; González CD; Sáenz C
    Acta Physiol Pharmacol Ther Latinoam; 1997; 47(4):197-202. PubMed ID: 9504179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the physicians' approach to the diagnosis and treatment of patients with antituberculosis drug-induced hepatotoxicity.
    Thongraung W; Sittidach M; Khwansuwan P; Sariyasuntorn K; Wongsampan S
    J Eval Clin Pract; 2012 Dec; 18(6):1119-25. PubMed ID: 21696520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy.
    Singh J; Garg PK; Tandon RK
    J Clin Gastroenterol; 1996 Apr; 22(3):211-4. PubMed ID: 8724260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity of antituberculous drugs.
    Rao NK; Wadia RS; Karve SR; Grant KB
    J Assoc Physicians India; 1982 May; 30(5):295-8. PubMed ID: 7169440
    [No Abstract]   [Full Text] [Related]  

  • 12. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
    Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The adverse reactions of anti-tuberculosis drugs and its management].
    Wada M
    Nihon Rinsho; 1998 Dec; 56(12):3091-5. PubMed ID: 9883616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring and management of antituberculosis drug induced hepatotoxicity.
    Agal S; Baijal R; Pramanik S; Patel N; Gupte P; Kamani P; Amarapurkar D
    J Gastroenterol Hepatol; 2005 Nov; 20(11):1745-52. PubMed ID: 16246196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
    Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CLINICAL EFFECTS OF TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS AT A SPECIALIZED HOSPITAL IN 2011].
    Okumura M; Sasaki Y; Yoshiyama T; Matsuda S; Osawa T; Morimoto K; Yanai H; Kurasima A; Ogata H; Gotoh H
    Kekkaku; 2015 Oct; 90(10):665-70. PubMed ID: 26821395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
    Singh J; Garg PK; Thakur VS; Tandon RK
    Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management].
    Aouam K; Chaabane A; Loussaïef C; Ben Romdhane F; Boughattas NA; Chakroun M
    Med Mal Infect; 2007 May; 37(5):253-61. PubMed ID: 17336011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective survey of drug induced hepatotoxicity in a large hospital.
    Kshirsagar NA; Karande SC; Potkar CN
    Indian J Gastroenterol; 1992 Jan; 11(1):13-5. PubMed ID: 1551705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiology of the resistance of Mycobacterium tuberculosis to antituberculosis drugs at the main hospital in Dakar, Senegal. A 4-year retrospective study (2000-2003)].
    Chevalier B; Margery J; Sane M; Camara P; Lefebvre N; Gueye M; Thiam M; Perrier-Gros-Claude JD; Simon F; Fabre M; Soler C; Herve V; Mbaye PS; Debonne JM
    Rev Pneumol Clin; 2010 Sep; 66(4):266-71. PubMed ID: 20933169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.